Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO/CAP Clinical Practice Guidelines.

Sambit K MohantySourav K MishraAnkit TiwariShivani SharmaMohit BhardwajNiharika PattnaikSunil JaiswalManas R BaisakhSubodh DasManas R PradhanTapas R SwainKaliprasad SatpathySean R WilliamsonAnil V Parwani

Published in: American journal of clinical pathology (2022)

Implementing 2018 guidelines, HER2 amplification decreased from 36 to 22 cases. The group with a HER2/CEP17 ratio of 2 or more and average HER2 copy number less than 4 (group 2) were predominantly negative by IHC, suggesting a biologically distinct group of HGUCa that is different from HER2-amplified tumors, which may not respond to HER2-targeted therapy.

Keyphrases

copy number
high grade
mitochondrial dna
nucleic acid
genome wide
dna methylation
gene expression
clinical practice
quality improvement
african american